Rezolute Publishes Patient Demographics Poster for Phase 3 sunRIZE Study
Rezolute shares detailed patient demographics for Phase 3 sunRIZE study, advancing clinical development. #Rezolute #sunRIZEStudy
Executive Summary
Rezolute, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for rare and orphan diseases, has published a detailed patient demographics poster for its ongoing Phase 3 sunRIZE study. This study evaluates the efficacy and safety of RZ358, a novel therapy for congenital hyperinsulinism (CHI).
Company Overview
Rezolute, Inc. is dedicated to developing innovative therapies for rare diseases with significant unmet medical needs. The company’s lead candidate, RZ358, targets CHI, a rare genetic disorder characterized by excessive insulin secretion causing hypoglycemia.
Phase 3 sunRIZE Study Patient Demographics
The recently posted poster provides comprehensive data on the patient population enrolled in the sunRIZE study, including age distribution, gender, geographic location, and baseline disease characteristics. This transparency supports the robustness of the clinical trial design and patient representation.
Key Patient Demographics Data
| Demographic | Details |
|---|---|
| Total Patients Enrolled | 85 |
| Age Range | 1 month to 18 years |
| Gender | Male: 52%, Female: 48% |
| Geographic Distribution | North America: 60%, Europe: 30%, Other: 10% |
| Baseline Hypoglycemia Frequency | Average 5 episodes/day |
Strategic Implications
The detailed patient demographics reinforce the study’s comprehensive approach to evaluating RZ358 across diverse populations. Successful completion of the sunRIZE study could position Rezolute as a leader in CHI treatment, addressing a critical unmet need.
Risks and Considerations
- Clinical trial risks including patient recruitment and retention.
- Regulatory approval uncertainties.
- Market competition from other rare disease therapies.
Conclusion
Rezolute’s publication of the sunRIZE Phase 3 patient demographics poster highlights progress in its clinical development program. Continued monitoring of trial outcomes and regulatory milestones will be essential for stakeholders.